Topics

Latest "Using Rapid Cycle Randomized Controlled Trials to Optimize the Influenza Clinical Decision Support Tool" News Stories

11:07 EDT 2nd April 2020 | BioPortfolio

Here are the most relevant search results for "Using Rapid Cycle Randomized Controlled Trials to Optimize the Influenza Clinical Decision Support Tool" found in our extensive news archives from over 250 global news sources.

More Information about Using Rapid Cycle Randomized Controlled Trials to Optimize the Influenza Clinical Decision Support Tool on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Using Rapid Cycle Randomized Controlled Trials to Optimize the Influenza Clinical Decision Support Tool for you to read. Along with our medical data and news we also list Using Rapid Cycle Randomized Controlled Trials to Optimize the Influenza Clinical Decision Support Tool Clinical Trials, which are updated daily. BioPortfolio also has a large database of Using Rapid Cycle Randomized Controlled Trials to Optimize the Influenza Clinical Decision Support Tool Companies for you to search.

Showing "Using Rapid Cycle Randomized Controlled Trials Optimize Influenza" News Articles 1–25 of 16,000+

Thursday 2nd April 2020

VirtualHealth and Divurgent Offer Personalized Patient Management to Battle COVID-19

Partnership offers tech-driven, patient-focused solution for healthcare organizations to triage and manage COVID-19 cases VirtualHealth, provider of


20172025 World Electronic Sphygmomanometer Market Research Report by Product Type, EndUser / Application and Regions / Countries [Published by HeyReport] Prices from USD $2800

SummaryElectronic sphygmomanometer is a device used to measure blood pressure, composed of an inflatable cuff to collapse and then release the artery under the cuff in a controlled manner, and a mercury or mechanical manometer to measure the pressure. It is always used in conjunction with a means to determine at what pressure blood flow is just starting, and at what pressure it is unimpeded. Manua...

MJH Life Sciences™ Acquires the Pharmacy Benefit Management Institute (PBMI)

MJH Life Sciences™ has announced it has acquired the Pharmacy Benefit Management Institute (PBMI) from Pharmaceutical Strategies Group (PSG). This latest addition to the MJH portfolio broadens its leadership position in managed care at a crucial time for medicine in our country. “Credible information is critical to healthcare professionals during this global pandemic, and education about ho...


Indonesia needs 'massive, rapid' testing for coronavirus

Indonesia needs to perform "massive" testing to reveal the full spread of the coronavirus and ensure that people who travel home during the approaching Muslim holiday isolate themselves, the governor of the archipelago's most populous province said. ...

PAION CLOSES ENROLLMENT IN EU PHASE III TRIAL WITH REMIMAZOLAM IN GENERAL ANESTHESIA

DGAP-News: PAION AG / Key word(s): Research Update 02.04.2020 / 13:00 The issuer is solely responsible for the content of this announcement. PAION CLOSES ENROLLMENT IN EU PHASE III TRIAL WITH REMIMAZOLAM IN GENERAL ANESTHESIA - 424 patients have been enrolled representing a sufficient number to conduct the planned statistical analyses - Data monitoring committee has ag...

ExxonMobil Joins Global Center to Expedite Medical Innovation for Personal Protective Equipment

Rapid design and deployment of reusable personal protection equipment for health care workers Multi-use equipment will help alleviate supply shortages for face shields and masks ExxonMobil to lend technical expertise and supply raw materials to help manufacture new reusable face masks ExxonMobil and the

The American Hospital Association and AVIA Launch New Tool to Support Members on the Front Lines of the COVID-19 Crisis: Introducing the COVID-19 Digital Response Pulse

Tool provides insights for hospitals and healthcare systems nationwide to combat the COVID-19 pandemic Today, the American Hospital Association (AHA) & AVIA are reaching out to all AHA members with a new tool for rapid, critical suppor

Accelerated Enrollment Solutions and Science 37 Collaborate to Provide Virtual Trial Access to Patients Globally

Also offers immediate telehealth options for clinical trials in response to need for social distancing and business continuity during COVID-19 pandemic Accelerated Enrollment Solutions (AES), a business of PPD, Inc. (Nasdaq:PPD), and

Rocket Pharmaceuticals Provides Business Update in Light of COVID-19 Pandemic

—Continue to Believe We Will Achieve 2020 Milestones— — Balance Sheet is Strong; Company Capital Will Be Sufficient into 2022 — Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today provides a business update in light of the COVID-19 pandemic. The Com...

Clinical trial of Gilead’s coronavirus hopeful remdesivir begins in UK

The pair of phase 3 trials will take place across 15 clinical sites in the UK

Company Profile for Atara Biotherapeutics, Inc.

Atara Biotherapeutics, Inc. is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases. Atara’s technology platform leverages research collaborations with leading academic institutions with the Company’s scientific, clinical, regulatory and manufacturing expertise. Atara’s pipeline includes tab-cel...

EMA advises malaria drugs use for trials only; FDA records shortage

The European Medicines Agency (EMA) has urged that two malaria drugs, chloroquine and hydroxychloroquine, being tested as potential Covid-19 treatment,...Read More... The post EMA advises malaria drugs use for trials only; FDA records shortage appeared first on Pharmaceutical Technology.

University Hospital Basel, Switzerland Transfuses First Two COVID-19 Patients With INTERCEPT Treated Coronavirus Convalescent Plasma

Cerus Corporation (Nasdaq: CERS) announced today that the University Hospital Basel transfused the first two COVID-19 patients with INTERCEPT treated coronavirus convalescent plasma (CCP). Cerus’ field team supported the INTERCEPT system implementation which was completed in one week. The University Hospital Basel and the regional blood transfusion service of the Swiss Red Cross, Basel initia...

Cerus Corporation Announces the Inclusion of Pathogen Reduction Technology in the ISBT Working Party Recommendations for the Preparation of COVID-19 Convalescent Plasma

Cerus Corporation (Nasdaq: CERS) announced today that the International Society of Blood Transfusion (ISBT) Working Party on Global Blood Safety issued a new document titled “Points to consider in the preparation and transfusion of COVID-19 convalescent plasma.” The document was authored by Dr. Jay Epstein and Dr. Thierry Burnouf, two key opinion leaders in the field of transfusion medicine. ...

Merrimack Divests Early Stage Asset for $2.25 Million; Provides Strategy Update

Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) [(“Merrimack” or the “Company”)] today announced receipt of $2.25 million in connection with the closing of a transaction in which the Company sold certain assets related to its preclinical nanoliposome programs to Celator Pharmaceuticals, Inc. Merrimack will not receive any further contingent consideration or royalties as a result of this tr...

Atara Biotherapeutics Provides Update in Context of COVID-19 Pandemic

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today provided an update in context of the COVID-19 (coronavirus) pandemic. “While this is an unprecedented time in history, Atara is working hard to ensure operational continuity to serve patients who...

Applied DNA and Takis Biotech Expand COVID-19 Vaccine Development Program to Include 5th Candidate

- Linear DNA Production for All Candidates Scheduled to Be Completed and Preclinical Animal Testing Expected to Commence This Month - Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”) a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing that enables diagnostics, pre-clinical nucleic acid-based therapeutic drug candidates, supply chain security, anti...

Dermavant Completes Patient Enrollment for Two Phase 3 Clinical Trials of Tapinarof for the Treatment of Psoriasis

- Tapinarof is a Potential First-in-Class Psoriasis Treatment with a Novel Mechanism of Action - - PSOARING 1 and PSOARING 2 are Two Identical Phase 3 Clinical Trials that have Enrolled a Combined 1,025 Patients to Evaluate the Safety and Efficacy of Tapinarof in Adult Patients with Plaque Psoriasis - - Dermavant Expects to Announce Results from PSOARING 1 and PSOARING 2 in 2H 2020 - - A Lo...

Horizon Therapeutics plc Acquires Curzion Pharmaceuticals, Inc. and Its LPAR1 Antagonist Product Candidate to Expand Development-Stage Pipeline

-- Gained Rights to Product Candidate, CZN001 (renamed HZN-825), a Potential Treatment for Diffuse Cutaneous Systemic Sclerosis; a Rare Rheumatic Disease with No FDA-Approved Treatment -- -- Compelling Fit with Horizon’s Strategy to Acquire and Develop Medicines Targeting Diseases with High Unmet Need with Focus on Its Core Therapeutic Areas -- Horizon Therapeutics plc (Nasdaq: HZNP) announc...

Noxopharm Investigating Potential COVID-19 Treatment

Noxopharm, a clinical-stage Australian oncology drug development company, has identified a clinical trial opportunity that could help reduce the mortality rate of COVID-19. Noxopharm has a primary focus on the development of Veyonda®, with the active ingredient, idronoxil.

Siemens Healthineers Releases Test Kit for Coronavirus COVID-19

Siemens Healthineers test kit will help detect SARS-CoV-2, the cause of COVID-19 Company is pursuing Emergency Use approvals from WHO and FDA for clinical use Siemens Healthineers announced today the availability of its molecular Fast Track Diagnostics (FTD) SARS-CoV-2 Assay test kit used to aid in the diagnosis of infection by the SARS-CoV-2 virus that causes the COVID-19 disease. Test kits...

Seattle Genetics Announces Potential Accelerated Approval Pathway in the U.S. for PADCEV™ (enfortumab vedotin-ejfv) in Combination with Immune Therapy Pembrolizumab as First-Line Treatment for Advanced Urothelial Cancer

Seattle Genetics, Inc. (Nasdaq:SGEN) today provided an update on the phase 1b/2 multicohort EV-103 trial (also known as KEYNOTE-869) of PADCEVTM (enfortumab vedotin-ejfv) in combination with anti-PD-1 therapy pembrolizumab for the treatment of patients with unresectable locally advanced or metastatic urothelial cancer who are unable to receive cisplatin-based chemotherapy in the first-line settin...

Cortexyme Presents Data Supporting Role of P. Gingivalis in Alzheimer’s Pathology at Advances in Alzheimer’s and Parkinson’s Therapies Virtual Focus Meeting 2020

-- New results demonstrate P. gingivalis’ ability to infect neurons and cause characteristic Alzheimer’s pathology -- Cortexyme’s lead compound, COR388, targets gingipains produced by P. gingivalis and is currently under investigation in the Phase 2/3 GAIN Trial Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic ap...

Axial Biotherapeutics Announces Positive Topline Results from Phase 1b/2a Clinical Trial of AB-2004 for the Treatment of Autism Spectrum Disorder

Axial Biotherapeutics, a biotechnology company dedicated to building a unique class of gut-targeted programs for neurodegenerative diseases and neurodevelopmental disorders, today announced positive topline data from its Phase 1b/2a clinical trial of AB-2004, a first-in-class therapeutic that removes certain metabolites from the gastrointestinal (GI) tract for the treatment of Autism Spectrum Dis...

TISSIUM Receives CE Mark and Announces Manufacturing Compliance Certification from TÜV SÜD

Received CE Mark for its first sterile biodegradable sealant in a pre-filled syringe format Issuance of new certifications from TÜV SÜD for TISSIUM's innovative products TISSIUM, a privately-owned life science company developing fully synthetic, biomorphic programmable polymers, announced the receipt of a CE-mark for its sterile biodegradable sealant in a pre-filled syringe. TISSIUM also a...


Quick Search

News Quicklinks